Incyte (INCY) Q4 Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Incyte (INCY) PT Raised to $175 at BMO Capital; 'We Like Risk/Reward Heading into ECHO-301'
February 15, 2018 3:06 PM ESTBMO Capital raised its price target on Incyte (NASDAQ: INCY) to $175.00 (from $172.00) while maintaining an Outperform rating.
Analyst M. Ian Somaiya commented, "Despite strong fundamentals and a rich pipeline, investor focus remains singularly on the upcoming epacadostat Phase 3 melanoma data (ECHO-301), with positive... More
UPDATE: SunTrust Robinson Humphrey Reiterates Bullish View on Incyte (INCY)
February 15, 2018 2:35 PM EST(Updated - February 15, 2018 2:50 PM EST)
(updated to expand analyst comment)
SunTrust Robinson Humphrey analyst Peter Lawson reiterated a Buy rating and $155 price target on Incyte (NASDAQ: INCY)
Lawson calls Q4 "Minor Jakafi Miss, but Focus on Epacadostat Readouts in 2018." The... More
